Tryptamine Therapeutics Issues 47 Million Unquoted Options

TipRanksDec 2 00:47 ET

Tryptamine Therapeutics Completes Dosing of First Subject in Obesity Study

MT NewswiresNov 21 21:39 ET

Tryptamine Therapeutics Doses First Patient in IV-infused Psilocin Phase 1b Study

Investing.com Nov 21 18:10 ET

Tryptamine to Plug $6M Placement Funding Into Acceleration of IV-infused Psilocybin Treatment Trials

The Market HeraldOct 29 19:59 ET

Tryptamine Therapeutics A$6 Million Placement Cornerstoned by Merchant Biotech Fund and Dr Daniel Tillett | ASX:TYP, OTC:TYPTF

Proactive InvestorsOct 29 19:49 ET

Tryptamine Therapeutics Plans Capital Raising Amid Trading Halt

TipRanksOct 27 22:37 ET